Navigation Links
Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Date:7/19/2010

MONTREAL and HONG KONG, China, July 19 /PRNewswire/ - Aegera Therapeutics Inc. released today encouraging survival data from the Phase 1 portion of its Phase 1-2 Study of the novel targeted therapeutic, AEG35156, given in combination with sorafenib in patients with advanced hepatocellular carcinoma (primary liver cancer).

This study, entitled "A Phase 1-2, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination with Sorafenib in Patients With Advanced Hepatocellular Carcinoma", is being conducted exclusively in Hong Kong.

The interim data, derived from the analysis of the 13 patients treated in the Phase 1 portion of this trial indicates that AEG35156 not only appears to be well tolerated when given in combination with sorafenib but may also prolong progression-free and overall survival when compared to historical data where patients were treated with sorafenib alone. Indeed, median progression-free survival of the Phase 1 patients was about 4 months and overall survival about 10 months. This data compares favorably with the median progression-free survival of 2.8 months and overall survival of 6.5 months noted in the sorafenib Phase 3 registration trial performed in the Asia Pacific region in a similar patient population.

"I am greatly encouraged by this interim data read and look forward to completing this study as quickly as possible to ascertain whether the improved survival data can be confirmed in the Phase 2 portion of the trial." declared Dr. Jacques Jolivet, Senior Vice-President, Clinical of the trial's sponsor, Aegera Therapeutics.

"We are excited about the results of the Phase I por
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
2. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
3. Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
4. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
5. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
10. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
11. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Nearly 20,000 medical professionals and healthcare leaders gathered ... Lab Expo in Chicago from ... research and technology that will advance medicine and get ... Wednesday, July 30, more than 19,500 attendees had registered ... Expo, with more than 10,000 of these attendees coming ...
(Date:7/31/2014)... sound-processing part of the mouse brain in a way ... in view. Their imaging technique allows zooming in and ... it enabled the team to watch brain cells light ... which represent a step toward better understanding how our ... journal Neuron . , In the past, researchers ...
(Date:7/31/2014)... Calif. , July 31, 2014 Rogne ... San Francisco Bay Area , has acquired a ... of Oxford,s commercialisation company. The potent anti-inflammatory activity of ... at the University of Oxford,s Sir William ... company, which has raised over $1.5 million in seed ...
(Date:7/31/2014)... , July 31, 2014 Research ... "Global Genomics Market 2014-2018" report to their ... Genomics is the study of the genetic material ... be a strong basis for the discovery and development ... human diseases or health conditions. Genomics is supported by ...
Breaking Biology Technology:Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3New mapping approach lets scientists zoom in and out as the brain processes sound 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... Madison, Wis. - The University of Wisconsin System ... patents, but ranks lower in transferring that technology to commercial ... included nearly 500 universities worldwide and more than 200 in ... of Santa Monica, Calif. In terms of number and ...
... soil. He also knows how to build a viable ... his ideas about turning landscape data into packaged products ... everywhere," said Rooney, founder and president of Earth ... the growing power of digital communications, he explained, creates ...
... Wis. - Raghu Ramakrishnan wishes he had a crystal ... driver in business. , ,Ramakrishnan, a vice president and research ... next great driver is search, which he called "the cash ... his preference trumps his hunch, it is user-generated content (combined ...
Cached Biology Technology:UW among top biotech patent producers 2Global information firm reaches diverse markets 2Global information firm reaches diverse markets 3Global information firm reaches diverse markets 4Online communities may be next business market 2Online communities may be next business market 3
(Date:7/30/2014)... at New York University is paving the way ... in civilians and military troops exposed to poisonous ... , An article in the current issue of ... in detoxifying organophosphates, which are compounds commonly used ... was developed by NYU School of Engineering Associate ...
(Date:7/30/2014)... Carroll,s Through the Looking Glass, collaborators from the ... improved a 35-year-old ecology model to better understand ... years. , The new model, called a mean ... Effect," an evolutionary hypothesis introduced by Lee Van ... must constantly increase their fitness (or ability to ...
(Date:7/30/2014)... that David L. Kaplan, Ph.D., will head the brand-new, ... as editor-in-chief. With the first issue slated for publication ... research in the rapidly burgeoning field of biomaterials, the ... with living or biological systems. , "This new journal ... the field of biomaterials over the past decade and ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... Children,s National Medical Center have discovered that ... are significantly more likely to have low levels of ... This study supports recent research that suggests vitamin D ... keeping bones healthy. Vitamin D deficiency has been recently ...
... March 17 Orbel,s innovative Board Shield ... PCB shield. Visit the BLS section   ... variety of surface mount or through-hole configurations. Then click ... lets you enter shield dimensions, mounting style, and ...
... In the 1930s, soil used as ballast to weigh down ... red imported fire ant to the southern United States. Since ... Maryland and as far west as California, shorting out streetlights ... Plant pests like the fire ant cost the U.S. ...
Cached Biology News:Study: Low levels of vitamin D linked to higher rates of asthma in African-American kids 2Orbel Introduces the Board Shielding Wizard 2From international harbor to native habitat 2From international harbor to native habitat 3
nucleophosmin (nucleolar phosphoprotein B23, numatrin), mRNA...
One-step, microplate or cuvet, colorimetric, detection range 0.78 ug/dL to 65 ug/dL Zn in serum, plasma, urine, saliva etc. Procedure: 10 min....
... Components: MBP Coated ... Assay Dilution Buffer, 5X, #20 Magnesium/ATP Cocktail, ... Buffer, 10X LumiGLO™ Chemiluminescen LumiGLO™ Chemiluminescen ... enzyme assay Quality Assurance: ...
Rabbit Serum New Zealand or California Origin...
Biology Products: